trending Market Intelligence /marketintelligence/en/news-insights/trending/LKovrvpF47YaZ3mc30pOCg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Spectrum withdraws application for blood disorder drug as US FDA seeks more data

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Spectrum withdraws application for blood disorder drug as US FDA seeks more data

Spectrum Pharmaceuticals Inc. voluntarily withdrew its application seeking approval of its drug Rolontis to treat a blood disorder after the U.S. Food and Drug Administration requested additional manufacturing-related information for the medicine.

Henderson, Nev.-based Spectrum submitted a biologics license application in December 2018 for Rolontis, or eflapegrastim, to treat chemotherapy-induced neutropenia. Neutropenia is an abnormally low concentration of neutrophils, a type of white blood cell, in the blood due to chemotherapy. The destruction of these cells leaves the body vulnerable to infections.

Spectrum said in its March 15 press release that the FDA did not cite concerns related to the clinical modules of the application or the need for any additional clinical studies.

The company voluntarily withdrew its application as it needed more time to provide certain manufacturing-related information before March 29, the date when the FDA's initial 60-day review period ends.

Spectrum's President and CEO Joe Turgeon said the company was having discussions with the FDA and will resubmit the application with the required information.